Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	2.70B +24.5%
Revenue (ttm)	412.51M -7.6%
Net Income	37.59M +8.8%
EPS	0.42 +9.9%
Shares Out	88.59M
PE Ratio	73.05
Forward PE	n/a
Dividend	0.22 (0.71%)
Ex-Dividend Date	Jun 12, 2025

Volume	1,154,005
Average Volume	1,241,776
Open	31.10
Previous Close	31.07
Day's Range	30.44 - 31.20
52-Week Range	27.51 - 39.28
Beta	0.44
RSI	49.54
Earnings Date	Apr 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 524
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2025, SHE:301258's revenue was 432.73 million, an increase of 0.76% compared to the previous year's 429.47 million. Earnings were 64.29 million, an increase of 291.89%.